US5534263A
(en)
*
|
1995-02-24 |
1996-07-09 |
Alza Corporation |
Active agent dosage form comprising a matrix and at least two insoluble bands
|
CA2173818A1
(fr)
*
|
1996-04-10 |
1997-10-11 |
Francois Chouinard |
Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
|
US5804165A
(en)
*
|
1996-07-24 |
1998-09-08 |
Arnold; Michael J. |
Antiplaque oral composition
|
DE19640062B4
(de)
*
|
1996-09-28 |
2006-04-27 |
Lts Lohmann Therapie-Systeme Ag |
Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff
|
US6046177A
(en)
*
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
IT1294760B1
(it)
*
|
1997-09-03 |
1999-04-12 |
Jagotec Ag |
Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
|
IN186245B
(de)
*
|
1997-09-19 |
2001-07-14 |
Ranbaxy Lab Ltd |
|
GB9724186D0
(en)
|
1997-11-14 |
1998-01-14 |
British Tech Group |
Low temperature coatings
|
CN1155388C
(zh)
*
|
1997-12-22 |
2004-06-30 |
先灵公司 |
利巴韦林口服固体剂型及其制备方法
|
ATE295184T1
(de)
*
|
1998-06-05 |
2005-05-15 |
Warner Lambert Co |
Stabilisierung von zusammensetzungen enthaltend ace-hemmer durch magnesiumoxid
|
CN1531421A
(zh)
*
|
1998-09-25 |
2004-09-22 |
�¶���˹ҩƷ��˾ |
口服给予的液体药物
|
CA2354057C
(en)
|
1998-12-11 |
2009-02-10 |
Nostrum Pharmaceuticals, Inc. |
Sustained release tablet containing hydrocolloid and cellulose ether
|
US6797283B1
(en)
|
1998-12-23 |
2004-09-28 |
Alza Corporation |
Gastric retention dosage form having multiple layers
|
US6635281B2
(en)
|
1998-12-23 |
2003-10-21 |
Alza Corporation |
Gastric retaining oral liquid dosage form
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
US6432448B1
(en)
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
MY121470A
(en)
*
|
1999-05-03 |
2006-01-28 |
Ranbaxy Lab Ltd |
Stable solid pharmaceutical compositions containing enalapril maleate
|
US6555139B2
(en)
|
1999-06-28 |
2003-04-29 |
Wockhardt Europe Limited |
Preparation of micron-size pharmaceutical particles by microfluidization
|
FR2797185B1
(fr)
*
|
1999-08-06 |
2001-10-26 |
Galenix Dev |
Composition pharmaceutique flottante comprenant une phase active et une phase non active
|
US6500462B1
(en)
|
1999-10-29 |
2002-12-31 |
Fmc Corporation |
Edible MCC/PGA coating composition
|
JP4565456B2
(ja)
*
|
1999-11-02 |
2010-10-20 |
塩野義製薬株式会社 |
着色顆粒の色素定着法
|
US6399101B1
(en)
|
2000-03-30 |
2002-06-04 |
Mova Pharmaceutical Corp. |
Stable thyroid hormone preparations and method of making same
|
AR030557A1
(es)
*
|
2000-04-14 |
2003-08-27 |
Jagotec Ag |
Una tableta en multicapa de liberacion controlada y metodo de tratamiento
|
US7985420B2
(en)
*
|
2000-04-28 |
2011-07-26 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US7838032B2
(en)
*
|
2000-04-28 |
2010-11-23 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin
|
US6372252B1
(en)
|
2000-04-28 |
2002-04-16 |
Adams Laboratories, Inc. |
Guaifenesin sustained release formulation and tablets
|
US6955821B2
(en)
|
2000-04-28 |
2005-10-18 |
Adams Laboratories, Inc. |
Sustained release formulations of guaifenesin and additional drug ingredients
|
US8012504B2
(en)
*
|
2000-04-28 |
2011-09-06 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US6881420B2
(en)
|
2000-06-23 |
2005-04-19 |
Teva Pharmaceutical Industries Ltd. |
Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
|
JP2004501190A
(ja)
*
|
2000-06-23 |
2004-01-15 |
テバ ファーマシューティカル インダストリーズ リミティド |
治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形
|
US6476006B2
(en)
|
2000-06-23 |
2002-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
|
US7674480B2
(en)
*
|
2000-06-23 |
2010-03-09 |
Teva Pharmaceutical Industries Ltd. |
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
|
DE10031043A1
(de)
|
2000-06-26 |
2002-02-14 |
Bayer Ag |
Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
|
US20060099245A1
(en)
*
|
2000-08-01 |
2006-05-11 |
Manoj Kumar |
Hydrodynamically balancing oral drug delivery system with biphasic release
|
BR0115585A
(pt)
|
2000-11-28 |
2005-12-13 |
Fmc Corp |
Composições de revestimento de pronta liberação, endurecìvel, comestìvel, seca e, úmida, forma de dosagem sólida, e, método para revestir uma forma de dosagem sólida farmacêutica ou veterinária, confeito, semente, ração animal, fertilizante, comprimido de pesticida ou alimento
|
EP1347748A2
(de)
*
|
2000-12-05 |
2003-10-01 |
MacGregor, Alexander |
Hydrostatisches abgabesystem für die kontrollierte abgabe eines mittels
|
KR100685945B1
(ko)
|
2000-12-29 |
2007-02-23 |
엘지.필립스 엘시디 주식회사 |
액정표시장치 및 그 제조방법
|
US8268333B2
(en)
*
|
2001-04-24 |
2012-09-18 |
Lintec Corporation |
Orally administered agent and an orally administered agent/supporting substrate complex
|
DE10120092B4
(de)
*
|
2001-04-25 |
2008-03-20 |
Lts Lohmann Therapie-Systeme Ag |
Magensaftresistente Vorrichtung zur Freisetzung von mukoadhäsiven Wirkstoffträgern und Verfahren zur Herstellung der magensaftresistenten Vorrichtung
|
IL159812A0
(en)
*
|
2001-07-12 |
2004-06-20 |
Teva Pharma |
Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
|
IL159813A0
(en)
*
|
2001-07-12 |
2004-06-20 |
Teva Pharma |
Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
US20030104052A1
(en)
*
|
2001-10-25 |
2003-06-05 |
Bret Berner |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
CA2409552A1
(en)
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
WO2003042136A2
(en)
*
|
2001-11-13 |
2003-05-22 |
Teva Pharmaceutical Industries, Ltd. |
Process for the production of l-dopa ethyl ester
|
US20030099699A1
(en)
*
|
2001-11-13 |
2003-05-29 |
Hanshew Dwight D. |
Storage stable thyroxine active drug formulations and methods for their production
|
US6645526B2
(en)
|
2001-11-13 |
2003-11-11 |
Mylan Pharmaceuticals, Inc. |
Storage stable thyroxine active drug formulations and methods for their production
|
WO2003041646A2
(en)
|
2001-11-13 |
2003-05-22 |
Teva Pharmaceutical Industries, Ltd. |
L-dopa ethyl ester salts and uses thereof
|
MXPA04006159A
(es)
*
|
2001-12-21 |
2005-03-31 |
Biopartners Gmbh |
Granulado de ribavirina para producir tabletas cubiertas.
|
KR20030056474A
(ko)
*
|
2001-12-28 |
2003-07-04 |
한국유나이티드제약 주식회사 |
카르비도파/레보도파 서방정의 조성물과 그의 제조방법
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
US7008979B2
(en)
*
|
2002-04-30 |
2006-03-07 |
Hydromer, Inc. |
Coating composition for multiple hydrophilic applications
|
US20060013875A1
(en)
*
|
2002-05-29 |
2006-01-19 |
Impax Laboratories, Inc. |
Combination immediate release controlled release levodopa/carbidopa dosage forms
|
US20040005359A1
(en)
*
|
2002-06-27 |
2004-01-08 |
Cheng Xiu Xiu |
Controlled release oral dosage form
|
AU2003270778B2
(en)
|
2002-09-20 |
2009-10-08 |
Alpharma Pharmaceuticals, Llc |
Sequestering subunit and related compositions and methods
|
TWI319713B
(en)
*
|
2002-10-25 |
2010-01-21 |
|
Sustained-release tramadol formulations with 24-hour efficacy
|
US8487002B2
(en)
*
|
2002-10-25 |
2013-07-16 |
Paladin Labs Inc. |
Controlled-release compositions
|
UY28056A1
(es)
*
|
2002-10-31 |
2003-12-31 |
Alza Corp |
Formas de dosificacion que proporcionan la liberacion ascendente de una formulacion liquida.
|
US8906413B2
(en)
|
2003-05-12 |
2014-12-09 |
Supernus Pharmaceuticals, Inc. |
Drug formulations having reduced abuse potential
|
US20050013863A1
(en)
*
|
2003-07-18 |
2005-01-20 |
Depomed, Inc., A Corporation Of The State Of California |
Dual drug dosage forms with improved separation of drugs
|
TWI372066B
(en)
*
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
US20060172006A1
(en)
*
|
2003-10-10 |
2006-08-03 |
Vincent Lenaerts |
Sustained-release tramadol formulations with 24-hour clinical efficacy
|
JP2005132803A
(ja)
*
|
2003-10-31 |
2005-05-26 |
Ono Pharmaceut Co Ltd |
胃内滞留固形剤
|
WO2005058319A1
(en)
*
|
2003-12-16 |
2005-06-30 |
Cnsbio Pty Ltd |
Methods and compositions
|
EP1750717B1
(de)
*
|
2004-02-11 |
2017-07-19 |
Rubicon Research Private Limited |
Pharmazeutische zusammensetzungen mit kontrollierter freisetzung und verbesserter bioverfügbarkeit
|
JPWO2005084703A1
(ja)
*
|
2004-03-09 |
2007-11-29 |
株式会社Nrlファーマ |
徐放性の口腔用組成物
|
FR2874325B1
(fr)
*
|
2004-08-19 |
2006-10-20 |
Sanofi Synthelabo |
Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
|
ES2531735T3
(es)
*
|
2004-10-15 |
2015-03-18 |
Supernus Pharmaceuticals, Inc. |
Preparaciones farmacéuticas con menor potencial de abuso
|
US20060141001A1
(en)
*
|
2004-11-19 |
2006-06-29 |
Finkelmeier Steven D |
Pharmaceutical product
|
US20060246003A1
(en)
*
|
2004-12-27 |
2006-11-02 |
Eisai Co. Ltd. |
Composition containing anti-dementia drug
|
US20060280789A1
(en)
*
|
2004-12-27 |
2006-12-14 |
Eisai Research Institute |
Sustained release formulations
|
JP2008525313A
(ja)
*
|
2004-12-27 |
2008-07-17 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
抗痴呆薬の安定化方法
|
US20090208579A1
(en)
*
|
2004-12-27 |
2009-08-20 |
Eisai R & D Management Co., Ltd. |
Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
|
US20060159753A1
(en)
*
|
2004-12-27 |
2006-07-20 |
Eisai Co. Ltd. |
Matrix type sustained-release preparation containing basic drug or salt thereof
|
US20070003621A1
(en)
*
|
2005-06-23 |
2007-01-04 |
Spherics, Inc. |
Dosage forms for movement disorder treatment
|
AU2006263338A1
(en)
*
|
2005-06-29 |
2007-01-04 |
Panacea Biotec Ltd. |
Pharmaceutical sustained release compositions and processes thereof
|
BRPI0615860B8
(pt)
*
|
2005-09-09 |
2021-05-25 |
Labopharm Barbados Ltd |
composição farmacêutica de liberação prolongada monolítica sólida
|
NL2000281C2
(nl)
|
2005-11-02 |
2007-08-07 |
Pfizer Prod Inc |
Vaste farmaceutische samenstellingen die pregabaline bevatten.
|
US8187633B2
(en)
|
2005-11-03 |
2012-05-29 |
Sun Pharma Advanced Research Company Limited |
Controlled release coated tablets having prolonged gastric retention
|
US20070178149A1
(en)
*
|
2005-11-07 |
2007-08-02 |
Moshe Flashner-Barak |
Levodopa compositions
|
US7674396B2
(en)
*
|
2005-11-08 |
2010-03-09 |
Plensat Llc |
Method and system for treatment of eating disorders
|
US8691272B2
(en)
*
|
2005-12-30 |
2014-04-08 |
Intelgenx Corp. |
Multilayer tablet
|
KR100752417B1
(ko)
*
|
2006-02-14 |
2007-08-28 |
대원제약주식회사 |
안정성이 증진된, 마진돌을 포함하는 약제학적 조성물
|
US9011930B2
(en)
*
|
2006-05-01 |
2015-04-21 |
Zycal Bioceuticals Healthcare Company, Inc. |
Nutritional supplement and use thereof
|
EP2021005A4
(de)
*
|
2006-05-03 |
2009-11-25 |
Cnsbio Pty Ltd |
Verfahren und zusammensetzung zur behandlung von entzündlichen schmerzen
|
JP2009538901A
(ja)
*
|
2006-06-01 |
2009-11-12 |
デクセル ファーマ テクノロジーズ エルティーディー. |
複式ユニット製薬的製剤
|
MX2008016372A
(es)
|
2006-06-19 |
2009-05-28 |
Alpharma Inc |
Composiciones farmaceuticas.
|
US20080131492A1
(en)
*
|
2006-06-23 |
2008-06-05 |
Spherics, Inc. |
Dosage forms for movement disorder treatment
|
CA2662122A1
(en)
*
|
2006-08-30 |
2008-03-06 |
Jagotec Ag |
Controlled release solid oral dosage formulations comprising nisoldipine
|
WO2008039193A2
(en)
*
|
2006-09-26 |
2008-04-03 |
Plensat, Llc |
Method and system for treatment of eating disorders
|
EP2066303B1
(de)
*
|
2006-09-26 |
2016-05-04 |
Plensat, LLC |
System zur behandlung von essstörungen
|
WO2008041553A1
(fr)
|
2006-09-26 |
2008-04-10 |
Astellas Pharma Inc. |
Préparation à libération entretenue de tacrolimus
|
EP1935411A1
(de)
|
2006-12-15 |
2008-06-25 |
Campina Nederland Holding B.V. |
Langsam freisetzender Hilfsstoff und seine Verwendung
|
WO2008079404A2
(en)
*
|
2006-12-22 |
2008-07-03 |
Combinatorx, Incorporated |
Pharmaceutical compositions for treatment of parkinson's disease and related disorders
|
CA2674039A1
(en)
*
|
2006-12-28 |
2008-07-17 |
Astellas Pharma Inc. |
Sustained release formulation for tacrolimus
|
AT505225A1
(de)
|
2007-04-26 |
2008-11-15 |
Sanochemia Pharmazeutika Ag |
0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
AU2009268934A1
(en)
*
|
2008-06-16 |
2010-01-14 |
Appian Labs, Llc |
Composition and method of preparation of release systems for constant (zero-order) release of active agents
|
ES2740360T3
(es)
*
|
2008-08-15 |
2020-02-05 |
Assertio Therapeutics Inc |
Composiciones farmacéuticas de retención gástrica para el tratamiento y la prevención de trastornos del SNC
|
MX2011003749A
(es)
*
|
2008-10-08 |
2011-09-01 |
Bioplus Life Sciences Pvt Ltd |
Sistema para suministrar medicamentos de liberacion sostenida.
|
WO2010048478A2
(en)
*
|
2008-10-23 |
2010-04-29 |
Appian Labs, Llc |
Tablets and discs with compartments with two or more drugs for release at certain intervals and with specific rates
|
US20100233259A1
(en)
*
|
2008-12-12 |
2010-09-16 |
Pascal Grenier |
Dosage form of ropinirole
|
EP2210585A1
(de)
|
2009-01-16 |
2010-07-28 |
Exelgyn |
Pharmazeutische SPRM-Zusammensetzungen, Behandlungsverfahren unter Anwendung dieser
|
US20100249423A1
(en)
*
|
2009-03-09 |
2010-09-30 |
Sanochemia Pharmazeutika Ag |
Tolperisone controlled release tablet
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
WO2011078993A1
(en)
|
2009-12-21 |
2011-06-30 |
Aptapharma, Inc. |
Functionally-coated multilayer tablets
|
TR201802207T4
(tr)
|
2010-03-29 |
2018-03-21 |
Astellas Pharma Inc |
Kontrollü Salımlı Farmasötik Bileşim.
|
JP5459670B2
(ja)
*
|
2010-05-07 |
2014-04-02 |
塩野義製薬株式会社 |
着色顆粒の色素定着化剤
|
US20130143867A1
(en)
*
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
AU2013213317B2
(en)
|
2012-01-23 |
2016-06-30 |
Sun Pharmaceutical Industries Limited |
In-situ multilayered tablet technology
|
CA2914365C
(en)
|
2013-06-05 |
2022-03-15 |
Synchroneuron, Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
MX369315B
(es)
|
2013-10-07 |
2019-11-05 |
Impax Laboratories Inc |
Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos.
|
US10987313B2
(en)
|
2013-10-07 |
2021-04-27 |
Impax Laboratories, Llc |
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
|
US10485758B2
(en)
|
2014-06-02 |
2019-11-26 |
Clexio Biosciences Ltd. |
Expandable gastroretentive dosage form
|
US9617230B2
(en)
|
2014-12-22 |
2017-04-11 |
Farmington Pharma Development |
Creatine prodrugs, compositions and methods of use thereof
|
EP3247384B1
(de)
|
2015-01-14 |
2023-10-04 |
The Regents of the University of Colorado, a body corporate |
In vitro verfahren zur diagnose von typ-1-diabetes mit insulinmimotopen
|
WO2016174664A1
(en)
|
2015-04-29 |
2016-11-03 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
CA3001337C
(en)
|
2015-10-09 |
2023-12-12 |
Reckitt Benckiser Llc |
Pharmaceutical formulation
|
EP3432877B1
(de)
|
2016-03-24 |
2023-01-11 |
ImmunoMolecular Therapeutics, Inc. |
D-alpha-methyldopa zur behandlung von autoimmunerkrankungen
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
WO2018102799A1
(en)
|
2016-12-02 |
2018-06-07 |
Clexio Biosciences Ltd. |
Gastric residence system
|
KR102039345B1
(ko)
*
|
2017-02-01 |
2019-11-01 |
지엘팜텍주식회사 |
프레가발린 함유 고팽윤성 서방성 삼중정제
|
CA3082184A1
(en)
|
2017-12-01 |
2019-06-06 |
Ultragenyx Pharmaceutical Inc. |
Creatine prodrugs, compositions and methods of use thereof
|
JP7296084B2
(ja)
|
2017-12-04 |
2023-06-22 |
クレキシオ バイオサイエンシーズ エルティーディー. |
長時間作用型胃滞留システム
|
JP2021506984A
(ja)
|
2017-12-18 |
2021-02-22 |
トリス・フアルマ・インコーポレーテツド |
トリガーパルス薬物放出を有する胃内滞留型raft形成システムを含む放出調節薬物粉末組成物
|
WO2019126215A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
WO2019126214A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
|
US11052060B2
(en)
|
2018-02-12 |
2021-07-06 |
The Regents Of The University Of Colorado, A Body Corporate |
Compounds and methods for treating autoimmunity
|
US11013707B2
(en)
|
2018-03-23 |
2021-05-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Administration of oral methyldopa
|
CN110214860A
(zh)
*
|
2019-07-10 |
2019-09-10 |
聂刘明 |
一种宠物饲料及其制备工艺
|
CN116801868A
(zh)
*
|
2021-07-30 |
2023-09-22 |
埃维西亚治疗公司 |
5-羟色氨酸胃滞留剂型
|
WO2023064598A1
(en)
|
2021-10-14 |
2023-04-20 |
Evecxia Therapeutics, Inc. |
A method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
|
WO2023214018A1
(en)
|
2022-05-06 |
2023-11-09 |
Galenix Innovations |
Gastro-retentive swellable sustained release composition
|